

UNITED STATES PARTMENT OF COMMERCE United States Pate and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20234

FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. APPLICATION NO. 09/580,491 05/30/00 HERTOGS K 07691.0009 **EXAMINER** 022852 HM12/0716 FINNEGAN, HENDERSON, FARABOW, GARRETT BORIN.M DUNNER LLP ART UNIT PAPER NUMBER 1300 I STREET, NW WASHINGTON DC 20005 1631 DATE MAILED: 07/16/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

Office Action Summary

Application No. 09/580,491

Applicant(s)

Michael Borin

Examiner

Art Unit 1631



Hertogs et al.

	The MAILING DATE of this communication appears	s on the cover sheet with the correspondence address	
	for Reply		
THE	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.		
af - If the be	ter SIX (6) MONTHS from the mailing date of this communion period for reply specified above is less than thirty (30) day be considered timely.	ys, a reply within the statutory minimum of thirty (30) days will	
co Failur - Any r	ommunication. re to reply within the set or extended period for reply will, b reply received by the Office later than three months after th	y period will apply and will expire SIX (6) MONTHS from the mailing date of py statute, cause the application to become ABANDONED (35 U.S.C. § 13 ne mailing date of this communication, even if timely filed, may reduce an	33).
ea Status	arned patent term adjustment. See 37 CFR 1.704(b).		
	Responsive to communication(s) filed on		_
2a) 🗌		ction is non-final.	
3) 🗆	Since this application is in condition for allowance closed in accordance with the practice under Ex pa	except for formal matters, prosecution as to the merits is arte Quayle, 1935 C.D. 11; 453 O.G. 213.	
Disposi	ition of Claims		
4) 💢	Claim(s) <u>1-30</u>	is/are pending in the application	٦.
4	la) Of the above, claim(s) <u>1-6 and 12-30</u>	is/are withdrawn from consider	atio
5) 🗆	Claim(s)	is/are allowed.	
6) 🗆	Claim(s)	is/are rejected.	
7) 🗆	Claim(s)		
8) 💢		are subject to restriction and/or election require	ement
Applica	tion Papers		
9) 🗆	The specification is objected to by the Examiner.		
10)□	The drawing(s) filed on is/a	re objected to by the Examiner.	
11)□	The proposed drawing correction filed on	is: வி approved வி disapproved.	
12)□	The oath or declaration is objected to by the Exam	niner.	
Priority	under 35 U.S.C. § 119		
	Acknowledgement is made of a claim for foreign p	priority under 35 U.S.C. § 119(a)-(d).	
a)	☐ All b)☐ Some* c)☐ None of:		
•	1. \square Certified copies of the priority documents have	ve been received.	
2	2. Certified copies of the priority documents have	ve been received in Application No	٤,
	3. \square Copies of the certified copies of the priority data application from the International Bure et the attached detailed Office action for a list of the		Í
Attachme	ent(s)		
	otice of References Cited (PTO-892)	18) Interview Summary (PTO-413) Paper No(s)	
	otice of Draftsperson's Patent Drawing Review (PTO-948)	19) Notice of Informal Patent Application (PTO-152)	
7) 🔲 Inf	formation Disclosure Statement(s) (PTO-1449) Paper No(s)	20) Other:	
			,

Serial Number: 09/580491

09/580491

Art Unit: 1631

DETAILED ACTION

Response to restriction requirement filed 04/27/00 is acknowledged. Applicant elected, with

Page 2

traverse, Group II, claims 7-11. Applicant argues that the search would not be burdensome because

of the group's similar or same classification. Where it is necessary to search for one of the distinct

subjects in places where no pertinent art to the other subject exists, a different field of search is

shown, even though the two are classified together. As stated in the requirement, the inventions are

unrelated as they have different modes of operation, different functions, or different effects. A

reference teaching, e.g., method of screening for drugs against one strain will not teach or suggest

method of screening for drugs against another strain or a method of determining drug sensitivity of

population. The restriction requirement is still deemed proper and is therefore made FINAL.

Claims 1-6,12-30 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as

being drawn to a non-elected groups.

Further restriction

Upon further consideration of the restriction requirement made in the previous Office action

the following additional election of species requirement was deemed necessary.

Election of species should be required prior to a search on the merits in all applications

containing both species claims and generic or Markush claims. (MPEP 808.01(a))

Serial Number: 09/580491

9/580491 Page 3

Art Unit: 1631

The claims of the Group are are individually or dependently directed to method of use of a

plurality of disclosed patentably distinct species nucleic acids. For the purposes of initial examination

on merits, applicant is required to elect a single disclosed species of each for

1) nucleic acids recited in the items a)-c) of claim 7, and

2) for species of mutants recited in each of the items a)-c) of claim 7.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed, even though the requirement

is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant

should submit evidence or identify such evidence now of record showing the species to be obvious

variants or clearly admit on the record that this is the case. In either instance, if the examiner finds

one of the inventions unpatentable over the prior art, the evidence or admission may be used in a

rejection under 35 U.S.C. 103(a) of the other invention.

To be complete, a response to the election of species requirement should include a proper

election along with a listing of all claims readable thereon, including any claims subsequently added.

MPEP 809.02(a).

Any inquiry concerning this communication or earlier communications from the examiner

should be directed to Michael Borin whose telephone number is (703) 305-4506. Dr. Borin can

normally be reached between the hours of 8:30 A.M. to 5:00 P.M. EST Monday to Friday. If

Serial Number: 09/580491 Page 4

Art Unit: 1631

attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. Michael Woodward, can be reached on (703) 308-4028. The fax telephone number for this group is (703) 305-3014.

Any inquiry of a general nature or relating the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

July 12, 2001

mlb

MICHAEL BORIN, PH.D PRIMARY EXAMINER